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We  have  recently  proposed  that  the  immune system's  idiotypic  repertoire 
includes a particular class of idiotopes that play an integral role in the regulation 
of immune responses (1, 2).  Hence, these idiotopes are designated as the regu- 
latory idiotopes and can be defined by the following criteria: (a) they function as 
autoimmunogens; (b)  they are shared by various members of an idiotype (Id) 1 
network pathway, which may consequently include antibodies with distinct anti- 
genic specificities; (c) they are recognized by regulatory T  cells that control the 
expression  of clones  expressing  them.  These  clones  possess  the  potential  of 
becoming dominantly expressed in an immune response because of the possible 
mediation of these regulatory T  cells that are either present before immunization 
or may be easily elicited during the course of an immune response (3). 
The notion that this special class of idiotopes exists was based on our study of 
the  immunochemical properties  of several  members  of an  idiotypic  network 
pathway, which was initiated by the immunization of normal BALB/c mice with 
ABPC-48 (A48), a BALB/c levan-binding myeloma protein. Immunization with 
A48 induced the synthesis of anti-A48 Id antibodies (Abe). In turn, immunization 
with Ab2 induced the synthesis of anti-(anti-A48 Id) (Abe), which expressed A48 
idiotopes. When Ab3 was used as an immunogen, it induced an antibody popu- 
lation termed anti-(anti[anti-A48  Id]) (Ab4), which bound not only to Ab3 but 
A48  as  well.  To  explain  this  result,  we  postulated  that  Abl  molecules must 
express an idiotope that is a member of a special set of regulatory idiotopes, the 
only strongly immunogenic idiotopes in a  syngeneic or autologous system. The 
Ab2 evoked by immunization with this Abl  does not bear any regulatory  idi- 
otopes.  Therefore,  any  subsequent  immunization with  Ab2  will  activate  only 
those cells that express  the  regulatory  idiotopes of Abl,  so the resulting Ab3 
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response  will  express  those  Ab~  idiotopes  as  well.  Thus,  the  Ab4  induced  by 
immunization with Abs is primarily made up of Abe-like antiregulatory idiotope 
molecules. Indeed, both Ab2 and Ab4 in our experiments bind to Abl as well as 
Ab3 (1). 
The A48  Id is normally not expressed  in detectable quantities in the sera of 
BALB/c mice that have been immunized with bacterial levan (BL), a  polyfruc- 
tosan containing primarily /3(2-6)  linkages.  Under  some circumstances,  nu/nu 
BALB/c  mice  will  produce  A48  Id-bearing  anti-BL  molecules  as  we  have 
previously described (4).  However, A48  Id-bearing anti-BL clones can be acti- 
vated to expression in BL-immunized BALB/c mice, by any one of three distinct 
treatments administered before antigenic challenge. These include: (a) adminis- 
tration of A48 Id-bearing monoclonal proteins to neonatal mice (5); (b) admin- 
istration of minute amounts of anti-A48 Id antibodies to neonatal mice (6); and 
(c) hyperimmunization of adult mice with anti-A48 Id antibodies conjugated to 
an immunogenic carrier such as keyhole limpet hemocyanin (KLH) (1). 
To thoroughly examine the properties of the members of the A48 Id network 
pathway, we prepared  a  panel of A48  Id  + monoclonal antibodies (MAb) from 
mice treated in each of the ways enumerated above.  Furthermore,  to test the 
prediction that regulatory idiotopes are shared by antibodies of many specificities, 
we  screened  a  sample  of  198  mouse  and  80  human  myeloma  proteins  for 
expression of the A48 Id. We found A48 Id expressed on one of these proteins, 
MOPC-167, a phosphocholine (PC)-binding mouse monoclonal protein. 
Materials and Methods 
Animals.  1-d-old BALB/c mice were obtained from breeding our colony at the Mount 
Sinai  School of Medicine, New York.  8-12-wk-old BALB/c, A/J, and SJL mice were 
obtained from The Jackson Laboratory, Bar Harbor, ME. 
Antigens.  BL from Aerobacter laevenicum was prepared according to a previously de- 
scribed technique (7). Inulin (Inu) (Calbiochem-Behring Corp., American Hoechst Corp., 
La Jolla, CA), was coupled to bovine serum albumin (BSA) according to Chien et al. (8). 
Cell Fusion.  Hybridomas were produced as described by Nowinsky et al. (9) using the 
SP2/0 plasmocytoma cell line. Polyethylene glycol 1000 (Sigma Chemical Co., St. Louis, 
MO), was used as the fusing agent. Cloning was performed by the limiting dilution method 
(9) using l0 s BALB/c thymocytes per well as the feeder layer. 
Myeloma Proteins and Monoclonal Antibodies.  Table I lists the isotype and origin of some 
of the  myeloma proteins and  monoclonal antibodies used in  this paper.  The  W3082 
myeloma protein was a gift of Mrs.  R. Lieberman (National Institutes of Health). The 
panel of 198  murine myeloma proteins that were screened for the A48 Id was kindly 
donated by Dr.  M.  Potter (NIH).  Likewise, the 80 human myeloma proteins screened 
were gathered from our own collection and those of Dr.  H. Kunkel (The Rockefeller 
University, New York) and Dr. D. Capra (University of Texas, Dallas). 
Labelling of Antibodies.  MAb were labeled with ~H amino acids in vitro according to 
the procedure of Kummer et al. (10) and modified by Inman (personal communication). 
~I-goat anti-mouse Ig was obtained from New England Nuclear, Boston, MA. Alkaline 
phosphatase labeling was carried out according to the methods previously described (5). 
Labeling of Sheep Erythrocytes (SRBC) with BL, Inu, and PC.  O-stearoyl derivatives of BL 
and Inu were prepared according to the method of Hammerling and Westphal (11), and 
were used to coat SRBC as previously described (7). PC-SRBC  were prepared  by the 
method of Cosenza (12). 
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and 3-76-42 were obtained by immunization of BALB/c mice with the Mab conjugated 
to KLH. The coupling of monoclonal proteins with KLH and the schedule of immuniza- 
tion have been described elsewhere (1). SJL anti-UPC-10 Id antibodies were prepared as 
described by Lieberman et al. (7). These anti-Id sera were depleted of anti-IgG~, allotype 
antibodies by adsorption on a  column of Sepharose 4B conjugated with the  BALB/c 
IgG2a myeloma protein RPC-5. Anti-Id antibodies were affinity purified by elution from 
Sepharose 4B columns conjugated with the monoclonal Ig used for immunization. 
Radioimmunoassay (RIA) Binding to Antigen.  The capacity of the monoclonal proteins to 
bind to various polysaccharides was studied as follows:  microtiter plates were coated for 
1 h at 37°C with BL (50 #g/ml) or Inu-bovine serum albumin (BSA) (5 #g/ml) in 0.02 
25  M borate buffer, pH 8.2. Platesfi  I-goat anu-mouse Ig antibodies (~50,000 cpm) (New 
England Nuclear). After extensive washing, the radioactivity bound to individual wells 
was measured in a gamma counter. 
Determination ofldiotypes.  Microtiter plates were coated for 1 h at 37°C with purified 
anti-Id antibodies (25 /gmg/ml) in 0.02  M borate buffer, pH 8.2, washed three times 
with saline, and then incubated for 1 h at 4°C with 3% BSA. After three more washings, 
the microplates were incubated for 18 h at 4 °C with SH-labeled MAb (i.e., A48, UPC-10, 
1-5-1,  2-11-3, and 3-76-42). After extensive washing, radioactivity bound to microtiter 
wells  was  measured in  a  liquid  scintillation counter.  In  other experiments, microtiter 
plates coated with anti-A48 Id antibodies were incubated with A48, MOPC-167, MOPC- 
511, MOPC-460 as previously described and then incubated for 18 h at 4°C with SH-goat 
anti-mouse IgA antibodies. These latter four myeloma proteins are all IgAk. 
Enzyme-linked Immunosorbent Assay (ELISA).  The  binding  ability  of  MAb  was  also 
measured by ELISA.  Microtiter plates (Dynatech Laboratories, Inc., Alexandria,  VA) 
were incubated for 18 h at 40C with BL (100 #g/ml) or Inu-BSA (5 #g/ml). After three 
washings with PBS containing 0.5% Tween, the microtiter plates were incubated for 18 
h at 4 °C with the MAb (10 #g/ml). After three further washings,  the plates were incubated 
with alkaline phosphatase-labeled goat anti-mouse Ig antibodies (1:200) (New England 
Nuclear). The capacity of A48 Id-bearing molecules to inhibit the binding of A48 by anti- 
A48 was also measured by ELISA. Microtiter plates were coated with purified anti-A48Id 
antibodies (5 #g/mi) for 18 h at 4°C and washed as previously described; various dilutions 
of inhibitors were then incubated for 3 h at 4°C. After three washings,  alkaline phospha- 
tase-labeled A48(1:100) was added for 18 h at 4°C to the microtiter plates. Microplates 
to which alkaline phosphatase-labeled antibodies had been added were washed three times 
with PBS-Tween 0.5%, and then incubated for 1 h at 37°C with p-nitrophenyl-phosphate 
in ethanolamine buffer pH 9.2, as previously described (9). The reaction was stopped by 
addition of 25 #i of 3 N NaOH to each well. The extent of the reaction was determined 
by measuring the absorbance of  each well at 405 nm in a micro ELISA spectrophotometer 
(Dynatech Laboratories, Inc.). 
Results 
Antigenic Spec~city of  Monoclonal Antibodies.  Hybridomas were prepared by the 
fusion of SP2/0 cells with spleen cells from three individual groups of mice that 
had been pretreated in the following ways: (a) injected with  10 ~g A48 mono- 
clonal protein at birth (series 1); (b) injected with 10 ng of anti-A48 Id antibodies 
at birth (series 2); or (c) immunized with a KLH-anti-A48 Id antibody conjugate, 
emulsified in  complete Freund's adjuvant as an adult  (series  3).  All  mice were 
immunized with  20 ug BL  1 mo after the completion of the pretreatment and 
their spleen cells were fused 3 d after antigenic challenge. 
Hybridomas arising from each set of fusions were screened for the ability of 
their culture supernatants to bind to BL as well as to inhibit the binding of 3H- 
A48 to anti-A48-coated plates in the radioimmunoassay (RIA). Among 49 MAb 
screened,  19  expressed  the  A48  Id  as  assessed  by these  criteria.  These  MAb 518  REGULATORY  IDIOTOPES 
were of the # or 73 isotypes (Table I). Among the 14 MAb obtained from mice 
pretreated  at  birth  with  A48  or anti-A48  Id,  8  bound  to BL  but  not to  Inu, 
whereas the remaining 6 bound both BL and Inu as assessed by hemagglutinin 
(HA) assay, RIA, and ELISA (Table II). Since Inu contains only/3(2-1) linkages, 
those  MAb that bind  BL but not Inu  should  be  considered  specific  for 13(2-6) 
linkages. The MAb which bind to both BL and Inu might be specific for 3(2-6) 
linkages only since both BL and Inu contain such linkages. However, it has been 
shown that Inu-binding  myeloma  proteins display 3(2-1),  3(2-6) cross-reactivity 
(4). Since the MAb in our series bound Inu quite weakly, we think it more likely 
that these antibodies are 32-6 specific and 32-1  cross-reactive. 
Among  the  five A48  Id  + MAb of series  3  (those prepared  from adult  mice 
hyperimmunized  with an anti-A48-KLH  conjugate), three lack binding activity 
for both BL and Inu, one displayed a low HA and ELISA titer to BL only, and 
one had a low binding titer for both BL and Inu. The BL-binding MAb (3-76-1 
and 3-76-38) may be regarded as expressing A48-1ike idiotopes. Since they bind 
BL considerably  less well than A48,  they must be considered as different from 
Abe, which initiated this pathway. The 3-76-12,  3-76-29, and 3-76-42 MAb may 
TABLE  I 
Origin and Isotypes of Monoclonal Antibodies 
Isotype  Origin of antibodies 
ABPC-48  a 
UPC-10  ~'2a 
W3082  a 
Series  1 
1-5-1  # 
1-3-1  # 
Series 2 
2-1-3  73 
2-18-4  # 
2-17-2 
2-11-3  # 
2-1-13  "r3 
2-1-1  # 
1-9-1  # 
2-14-1  73 
2-28-1 
2-12-3  # 
2-7-3  # 
Series 3 
3-76-1  3'3 
3-76-12  # 
3-76-29  # 
3-76-38  tz 
3-76-42  # 
BALB/c myeloma proteins 
Obtained by fusion of SP2/0 cells with spleen cells from BALB/c mice 
treated at birth with 10 #g A48 monoclonal protein and immunized 
with BL. 
Obtained by fusion of SP2/0 cells with spleen cells from BL-immunized 
BALB/c  mice treated  at  birth  with  10  ng syngeneic anti-A48  Id 
antibodies. 
Obtained by fusion of SP2/0 cells with spleen cells from BL-immunized 
BALB/c mice producing anti-(anti-A48  Id) antibodies subsequent to 
immunization  with anti-A48 Id-KLH conjugate in complete Freund's 
adjuvant. GOLDBERG,  PAUL,  AND  BONA 
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7  1,062 +  167  1.68  0  0  0.16 
9  2,144 + 71  1.80  0  0  0.03 
7  1,888 + 308  1.78  >12  2,895 + 99  1.76 
0  0  0.11  0  0  0.13 
4  958 + 48  1.75  0  22 + 78  0.01 
12  1,170+58  1.87  0  187+48  0.03 
5  1,279 + 33  1.58  1  221 + 42  0.06 
5  1,444 + 267  1.83  3  393 +  131  0.16 
3  909 + 223  1.59  0  0  0.03 
6  1,057 +  115  1.55  2  285+ 14  0.27 
5  1,159 + 24  1.61  0  0  0.07 
10  ND  ND  4  ND  ND 
8  1,173 +  125  1.61  1  157 + 82  0.21 
7  1,089 + 47  1.75  0  36 + 37  0.02 
7  1,106+68  1.19  0  54+37  0.10 
1  610 +  27  1.60  0  124 + 55  0 
2  920+ 119  1.40  2  299+ 10  0.30 
4  1,036 + 29  1.58  0  187 + 77  0.10 
1  466 +  148  0.31  0  0  0 
0  208 + 28  0.14  0  43 + 24  0 
0  194+89  0.13  0  180+70  0 
1  289+21  0.34  1  117+33  0.15 
0  78 + 34  0.02  0  0  0 
* In log2 units. ND, not done. 
* In cpm, mean + SD of triplicates. 
00D at 405 nm. 
be  either  molecules  bearing  an  A48-1ike  Id which  lack  BL binding  activity  or 
antibodies  specific  for  the  idiotopes  of anti-A48  Id  antibodies  (i.e.,  anti-anti- 
A48[Ab3] molecules). 
Expression of  A48 Id on Monoclonal Antibodies.  The presence of A48 Id on MAb 
was further studied in a  competitive inhibition  RIA. The data depicted in Fig.  1 
shows the degree of inhibition  of the binding of radiolabeled  A48 to syngeneic 
anti-A48  Id antibody-coated  plates,  caused  by the various  MAb: A48;  W3082; 
an Inu-binding myeloma protein known to express the cross-reactive (IdX) B, A, 
and  G;  and  MOPC-21.  W3082  and  MOPC-21  monoclonal  proteins  did  not 
inhibit the binding of 3H-A48 to anti-A48 Id. Two MAb from series  1, six MAb 
from series  2, and three  MAb from series  3  caused inhibition  at low concentra- 
tions (0.5-5 #g). Among  the latter three, only one had BL binding activity. The 
capacity  of  the  two  non-BL-binding  MAb  to  inhibit  in  this  assay  could  be 
explained either by their true expression of A48 Id or by their being specific for 
idiotopes on anti-A48. 
A48 Id Represents  a Family ofldiotopes.  Legrain  et al.  (13)  has  suggested  that 
the A48 Id is composed of several idiotopes. We investigated this possibility using 
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FIGURE  1.  Inhibition of binding of 3H-A48 to anti-A48 Id antibodies by series 1, 2, and 3 
MAb, and A48, MOPC-21, and W3082 monoclonal  proteins. 
TABLE III 
Percentage of Binding of 3H-A48, UPC-IO, 1-5-1, 2-11-3, and 3-76-42 Monoclonal Proteins to 
Anti-Id Antibodies 
Anti-Id antibodies 
Percent of binding 
A48  UPC-10  1-5-1  2-11-3  3-76-42 
BALB/c anti-A48  +100  +(61)  +(98)  +(161)  +(29) 
SJL anti-UPC-10  +(64)  +(100)  +(98)  +(36)  +(43) 
BALB/c anti-l-5-1  +(30)  +(62)  +(100)  +(74)  -(0) 
BALB/c anti-2-11-3  +(42)  +(48)  +(64)  +(100)  -(0) 
BALB/c anti-3-76-42  +(20)  +(63)  __.(5)  +(10)  +(I00) 
In this experiment microtiter plates were coated with anti-Id antibodies (25 #g/ml) and then with 
nil-labeled monoclonal proteins. The amount of radioactivity bound to their corresponding anti-Id 
antibodies was considered 100% (see italics)  and was compared with the binding to different anti-Id 
antibodies.  The  percentage was calculated as follows: [(cpm  binding to different anti-Id)  -  (cpm 
binding to BSA/(cpm binding to corresponding anti-Id -  cpm binding to BSA)]  ×  100.  Idiotopes 
were recognized by various anti-ld antibodies on monoclonal antibodies. 
UPC-10, and a representative 3H-MAb for each series (i.e., 1-5-1, 2-11-3, and 3- 
76-42)  to a  series of plates coated with anti-Id antibodies generated to each of 
these monoclonal proteins, Since the radioactive ligand is a monoclonal protein, 
the critical parameter is whether it was bound to anti-Id-coated plates or not. 
However,  we  observed  that  different anti-Id bound  different percentages  of 
ligand under our test conditions. This could be explained either by differences 
in the affinity of the anti-Id for the MAb or to the polyclonal nature of the anti- 
Id, which contains a  mixture of molecules only some of which are specific for 
the  MAb being tested.  We observed  (Table  III) that anti-A48  binds to A48, 
UPC-10, 1-5-1,  2-11-3, and 3-76-42, while anti-l-5-1 and -2-11-3 binds to A48, 
UPC-10,  1-5-1, and 2-11-3  but not to 3-76-42. This could indicate that A48 and 
UPC-10  bear  at  least two determinants (A481  and A482),  one  of which (i.e., 
A481) is not expressed on 3-76-42. Alternatively, 3-76°42 might be an anti-(anti- 
A48) that does not recognize the idiotopes of anti-1-5-1  or anti-2-11-13.  The 
capacity of anti-3-76-42  to bind weakly to  1-5-1 and 2-11-3  is consistent with GOLDBERG,  PAUL,  AND  BONA  521 
both possibilities. Another possibility is that 1-5-1 and 2-11-3 could express A481 
and A48~ sites although anti-l-5-1  and anti-2-11-3  lack antibodies specific for 
the A482 site.  Finally, anti-3-76-42  could be a  mixture of anti-Abs (i.e.,  Ab4) 
and Ab2-1ike (i.e., anti-A48-1ike) molecules. It would thus bind 3-76-42 well and 
A48,  1-5-1, and 2-11-3, poorly. An interesting result is that an SJL anti-UPC- 
10 antibody binds 3-76-42 well and conversely anti-3-76-42 binds UPC-10 well. 
Again, this is consistent with either 3-76-42 bearing an A48-Id or being an anti- 
(anti-A48 Id) antibody. However, for the latter to be correct, one must postulate 
that  SJL  anti-UPC-10  shares  idiotypes with  BALB/c  anti-A48  since  3-76-42 
binds both. 
Further information on the heterogeneity of the idiotopes expressed on A48 
and on the other MAb was obtained by studying the capacity of BL to inhibit 
the binding of radiolabeled MAb to anti-Id antibody-coated plates. The data in 
Fig. 2 show that the binding of A48 to anti-A48 Id antibodies was only partially 
inhibited by BL, indicating that these anti-Id antibodies recognized at least two 
families of idiotopes, one associated with the combining site (antigen inhibitable) 
and the other located outside the combining site (noninhibited by antigen). Anti- 
1-5-1  Id  antibodies  also  recognizes  both  antigen-inhibitable  and  nonantigen- 
inhibitable  determinants on  A48.  An analysis  of the  binding of these anti-Id 
antibodies  to  UPC-10  indicated  that  anti-A48  recognized  only  the  antigen- 
inhibitable  sites of UPC-10,  whereas anti-l-5-1  recognized A48  and  UPC-10 
antigen-inhibitable idiotypes. 
So  far,  these  results  indicate  that  A48  must  express  at  least  one  antigen- 
inhibitable site. However, further studies revealed that while anti-A48 recognizes 
an UPC-10 antigen-inhibitable site, anti-UPC-10, which also recognizes an UPC- 
!0  antigen-inhibitable  site,  fails  to  recognize  an  A48  antigen-inhibitable  site. 
These results are consistent with the presence of two antigen-inhibitable sites on 
A48, one shared with  UPC-10 and the other not.  However,  these results can 
also be explained by the absence of reciprocally cross-reactive antibody in the 
anti-UPC- 10 Id which implies that an antigen-inhibitable site exists that is shared 
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FIGURE 2.  Inhibition of binding of 3H-labeled A48, UPC-10,  and  1-5-1 to various anti-Id 
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conclusion that UPC-10 may have two antigen-inhibitable idiotopes, only one of 
which  is shared  by A48  but both are expressed on  1-5-1.  Neither anti-2-11-3 
nor anti-3-76-42  identifies antigen-inhibitable sites on A48,  UPC-10,  or  1-5-1. 
Furthermore, only anti-2-11-3  Id antibodies  detect an antigen-inhibitable  site 
on 2-11-3.  Since 3-76-42 does not bind BL, the ability of antigen to inhibit the 
binding  of  anti-Id  antibodies  to  these  molecules  could  not  be  tested.  The 
conclusions of the analysis of the expression of various idiotopes on A48,  UPC- 
10, and three MAb are illustrated in Table IV. 
Search for Expression  of A48 Id on a Sample of 198 Mouse and 80 Human Myeloma 
Proteins.  Thus  far,  A48  Id  have been shown  to be associated  with  MAb  that 
bind to BL and  Inu  as well as those which bind to BL only.  Nonetheless,  the 
series of MAb that bind BL do so relatively poorly. A  more stringent test of the 
A48 Id as regulatory idiotopes would be their expression on MAb that lack BL- 
or Inu-binding activity, since it is possible that the three MAb of series 3 which 
lack antigen-binding activity are antibodies to idiotopes of anti-A48-Id antibodies 
(i.e., Abs) rather than A48 Id-bearing molecules. Thus, we screened a sample of 
198 mouse and 80 human myeloma proteins for their expression of the A48 Id, 
by their  ability to  inhibit  the  binding  of A48  to anti-A48  Id antibody-coated 
plates by RIA and ELISA. Only MOPC-167, a mouse IgAk PC-binding myeioma 
protein gave a  significant inhibiton (Table V).  As shown in Table VI,  MOPC- 
TABLE IV 
Summa O, of Antigen Inhibition of ld-Anti-Id Interaction 
A48  UPC-10  I-5-1  2-11-3 3-76-42  Conclusion: idiotopes identified 
Anti-A48  P*  C  P  N  N  A48I*  A48 NI  U10 I 
Anti-UPC-10  N  P  P  N  N  A48I  U10 I  U10 NI 
Anti-l-5-1  P  C  P  N  N  A48I  A48 NI  U10 I 
Anti-2-11-3  N  N  N  N  N  A48 NI  U10 NI 
Anti-3-76-42  N  N  N  N  N  A48 NI  U10 NI 
* C, complete; P, partial; N, noninhibition. 
* I, antigen inhibitable; NI, antigen-noninhibitable idiotope(s). 
TABLE V 
Search for the Expression of A48 ld on Murine and Human Myeloma Proteins 
Antigen-binding  activity  A48 Idiotype 
Myeloma proteins  BL  lnu  PC  HA inhi-  RIA inhi- 
ELISA 
HA  RIA  HA  RIA  HA  RIA  bition  bition 
A48  11  4,824 + 694  0  171 + 296  0  0  8  5*  96* 
W3082  9  2,529 +  102  23  7,016 + 806  0  0  0  >5,000  0 
MOPC-167  0  682 + 389  0  0  7  2,538 +  130  0  50  52 
Other 197 murineland 80  ND  ND  ND  0  >5,000  >10 
human monoclonal pro- 
teins 
HA and HA inhibition titer are expressed  as iogt units.  Each protein was used as  1 mg/ml. RIA: Microtiter plates were coated with BL 50 
t~g/ml, Inu-BSA  5 #g, PC-BSA 5 #g, respectively,  and incubated with  10 #g/ml monoclonal  proteins.  The binding was measured  with tSSl- 
goat anti-mouse  Ig (10,000 cpm) and the nonspecific  binding to BSA-coated plates was substracted  from each value. 
* ng of monoclonal protein required to give 50% inhibition of binding of radiolabe|ed A48 to anti-A48 Id-coated  plates. 
* Percentage  of inhibition of alkaline phosphatase-labeled  A48 to anti-A48 Id antibodies obtained with 0.5 #g monoclonal  protein. 
!  197 murine monoclonal proteins sample  includes  EPC-109,  UPC-61, W3082, AMPC1. J606, all B2-6 and B2-1 fructosan-binding proteins 
that express  G, B, and A cross-reactive  idiotypes (4). GOLDBERG,  PAUL,  AND  BONA 
TABLE  VI 
Direct Binding of A48 and MOPC-167 to Anti-A48 Id Antibodies 
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Anti-A48 absorbed on A48-conjugated 
Sepharose beads 
Anti-A48 absorbed on 167-conjugated 
Sepharose beads 
cpm 
--  123 ±  50 
A48  2,856 +  142 
MOPC-167  2,783 ±  47 
MOPC-511  273 ±  25 
MOPC-460  398 ±  118 
A48  91 ±  78 
MOPC-167  0 
A48  317 +  80 
MOPC-167  0 
Microtiter plates were coated with purified anti-A48 Id antibodies followed by 
three washings in saline. The plates were incubated for  1 h with 3% BSA and, 
after three washings, incubated for 18 h at 4°C with various myeloma proteins, 
followed by three washings in saline and incubation with SH-goat anti-IgA. The 
direct binding of all-goat anti-lgA to anti-A48 Id antibodies was subtracted from 
each value. 
167 bound to anti-A48 Id antibody-coated plates to the same extent as A48, as 
assessed by the subsequent binding of purified all-goat anti-IgA antibody.  By 
contrast, MOPC-511, another IgAk PC-binding myeloma protein failed to bind 
to anti-A48 Id antibodies. Furthermore, the binding activity of anti-A48 for A48 
and for MOPC-167  was lost, if the anti-Id absorbed on either A48- or MOPC- 
167-conjugated Sepharose beads. 
PC-chloride  failed  to  inhibit  the  binding  of  alkaline  phosphatase-labeled 
MOPC-167 to anti-A48 Id antibodies, indicating that the idiotope(s) of MOPC- 
167 recognized by anti-A48 Id is not associated with the combining site. On the 
other hand,  strong inhibition was obtained with 0.1-10  ~g A48  and  3-76-42 
MAb in this ELISA,  suggesting that the A482,  the nonantigen-inhibitable  idi- 
otope expressed on A48 and 3-76-42 is shared with MOPC-167 (Fig. 3). These 
results  clearly  indicate  that  A48  regulatory  idiotopes  can  be  expressed  on 
antibodies with different antigenic specificities. 
Discussion 
We have previously proposed that antibodies able to achieve clonal dominance 
generally express a  special  type of idiotope (a  regulatory  idiotope) for  which 
specific regulatory T  cells and/or antibodies either preexisted or could be rapidly 
produced. Such regulatory idiotopes, we proposed, were expressed on antibodies 
at a much higher frequency than conventional idiotopes and could be found on 
antibodies of distinct specificities (1, 2). 
We  were  led  to  this  proposal  by  observations  in  our  study of a  "network 
pathway" initiated by immunization with the fructosan-binding myeloma protein 524  REGULATORY IDIOTOPES 
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FIGURE 3.  Inhibition  of binding of alkaline phosphatase-labeled  MOPC-167 to anti-A48 Id 
antibodies of PC-CL, BL, A48, UPC-10, and 3-76-42 monoclonal  proteins. 
A48 (1) and by similar results of Wikler et al. (14).  In these two systems, both 
the anti-Id (Ab2) and anti-(anti-[anti-Id]) (Ab4) molecules bound to the Id-bearing 
molecule (Abl) used to initiate the network pathway. We concluded that Ab4 
should consist of a majority of Abl-binding molecules if the immunogen against 
which it  was produced (Ab3)  resembled Abl  (1).  In  turn,  this  suggested that 
immunization with Ab~ preferentially activated molecules bearing Abi-like idi- 
otopes rather than anti-Ab2 paratopes. This, we reasoned, would indicate that B 
cells bearing Abe-like idiotopes were present at a  higher frequency (or could 
more easily be activated) than anti-Abe-bearing B cells. 
The study of the A48 Id, both as expressed on Abi molecules (A48 itself) as 
well as on the other members of the A48  network pathway was therefore of 
considerable importance. The results presented in this communication demon- 
strate a  sharing in  expression of idiotopes among A48,  UPC-10,  and MOPC- 
167.  The shared idiotype of the fructosan-binding proteins A48 and UPC-10, 
although not previously appreciated (5) is not surprising. Both are members of 
the VHIII subgroup and, in addition, the nucleotide sequences of the expressed 
genes of these two proteins indicated that a strong homology exists among amino 
acids 32-97 of the Vn regions. The sequence of the first 31 amino acids of A48 
is not available (15). The UPC-10 Vu gene, which has been completely analyzed, 
appears to be derived from the VH441  germ line gene. The MOPC-173 Vn gene 
also derives from this  germline gene and its also expresses some of A48-U 10 
idiotopes (Table VII). The UPC-10 and MOPC-173 Vn genes differ at only six 
positions.  Finally,  the  D  genes  of A48,  UPC-10,  and  MOPC-173  are  quite 
different from one another,  as are the J  genes which encode the C  terminal 
portion  of each  variable  region  (16).  These  results  would  suggest  that  the 
idiotypic sharing of A48-UPC-10 and MOPC-173  depends, at least in part, on 
VH gene similarities, although the contribution of L chain remains to be evalu- 
ated. 
MOPC-167, a PC-binding myeloma protein, also expresses A48 Id. The extent 
of its idiotypic sharing with A48 is illustrated by the finding that absorbing anti- 
A48 antibodies with Sepharose 4B beads to which MOPC-167  has been conju- 
gated, removes "-,90% of its A48-binding capacity. MOPC-167 also uses a VnIII GOLDBERG, PAUL, AND BONA 
TABLE VII 
Expression of A48 Id on MOPC-173 Monoclonal Proteins 
Microtiter plates coated with: 
Alkaline phosphatase-labeled 
ligands (1:500) 
A48  UPC-10 MOPC-173 
BSA  0*  0  0.02 
BL (10 #g/ml)  1.40  1.76  0 
Trinitrophenyl/BSA (5 #g/ml)  0  0.03  0 
Polyclonal anti-A48 (25 #g/ml)  1.31  0.13  0.08 
Monoclonal anti-A48 (25 #g/ml)  1.29  1.75  0.11 
(IDA 10) 
Polyclonal anti-UPC-10 (25 #g/ml)  0.79  1.75  1.95 
Polyclonal anti-MOPC-173 (25 t~g/  0  0.07  1.97 
ml) 
Monoclonal anti-460 (25 ug/ml)  0  0  0.04 
(FD.5-1.3) 
Polyclonal and monoclonal anti-A48 Id antibodies are syngeneic anti- 
bodies prepared in  BALB/c mice; polyclonal anti-UPC-10 Id is an 
allogeneic antibody prepared in SJL mice; polyclonal anti-MOPC-173 
and monoclonal anti-460 antibodies are allogeneic antibodies produced 
in A/J mice. 
OD at 405 nm. 
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subgroup H  chain.  However, the third CDR, the D region and the Jn region of 
A48 and MOPC-167, are very different from one another.  Indeed, MOPC-167, 
and UPC-10 show substantial homology only in the FR 1 segment of the Vn gene 
(17) suggesting that similarities in this part of the Vrt gene and/or the light chain 
are  critical  to  idiotypic  sharing.  MOPC-511,  which  lacks  A48  Id,  has  strong 
homology to MOPC-167 in its VH gene but differs from MOPC-167 in only six 
positions  in  the  amino  acid  sequence  of its  light  chain  (18).  Although  the 
structural analysis of these molecules (A48, UPC- 10, MOPC- 173, MOPC- 167) is 
not  sufficiently  complete  to  allow  the  precise  mapping  of the  A48-Id,  rapid 
progress in this area should provide important information in the near future. 
We attempted to obtain greater insight into the idiotopes of the A48-Id by the 
analysis of MAb generated from animals which had been pretreated with various 
components of the A48 network pathway and prior  to their being immunized 
with BL. All MAb of the first two series (i.e., from donors pretreated as neonates 
with A48 or anti-A48) that expressed the capacity to bind to anti-A48 were also 
capable of binding BL. This result strongly indicates that these molecules express 
an A48 Id. The combined analysis of the binding specificities ofanti-Id antibodies 
generated  to each of these MAb, and  the degree to which hapten  inhibits  the 
binding of these anti-Id to the MAb indicate that A48 expresses several idiotopes. 
A  minimum  estimate  is  that  theere  is at  least  one,  and  probably two hapten- 
inhibitable idiotopes, and one noninhibitable idiotope. 
The  analysis  of a  non-BL-binding  MAb  from  series  3  is  potentially  more 
important since it should allow a more rigorous demonstration of the regulatory 
idiotope concept. Our results cannot distinguish between the alternatives that 3- 
76-42, a non-antigen-binding  MAb, bears an A48 Id or is specific for an idiotope 
of anti-A48.  The regulatory idiotope concept would predict that  MAb such as 526  REGULATORY  IDIOTOPES 
3-76-42  should be mainly of the former type. In fact, Legrain and Buttin (19) 
have  recently analyzed  a  series  of seven  hybridomas  which  produced  non- 
antigen-binding MAb, produced from animals that had been immunized with 
monoclonal anti-A48 Id conjugated to KLH. They found that mRNA from five 
hybridomas hybridized with a  VH-441  cloned germ line DNA, suggesting that 
they were A48-1ike rather than anti-anti-A48 Id molecules. 
This interesting result strongly affirms the validity of the regulatory idiotope 
concept since the donor of the spleen cells used to form the hybridomas had not 
been boosted with BL. Thus, no antigenic stimulation favoring the expansion of 
A48 Id-bearing B cells over anti-A48 Id-specific B cells was provided. 
Others (D. L. Sacks, G. H. Kelsoe, and D. H. Sachs, personal communication) 
have recently pointed out that immunization with anti-A48 Id antibodies would 
be more likely to lead to stimulation of A48 Id  + B cells than of anti-(anti-A48 
Id) B cells even if the A48 Id was a conventional idiotope. They reasoned that 
anti-A48 Id antibodies share specificity for A48 Id but display idiotypic hetero- 
geneity. Thus, in immunization with anti-A48 Id, the concentration of Anti-A48 
paratopes is  high  but  the concentration of any individual anti-A48  Id is  low. 
Thus, A48 Id-bearing B cells would be expected to be activated more efficiently 
than  anti-A48  Id-specific  B  cells.  The  Legrain-Buttin  experiment described 
above (18)  constitutes an  especially important  test of the regulatory idiotope 
concept since they used MAb for immunization and, thus, paratope and idiotope 
concentration should be identical. The observation that the mRNA from five 
MAb expressing A48  Id hybridized with a  VH441  germ line gene probe,  and 
that two MAb specific for individual idiotopes of anti-A48 Id antibody did not 
hybridize, indicate that A48 Id  + B cells are activated in preference to anti-A48 
Id-specific B cells. Had the two types of B cell appeared in equal concentration, 
it would have suggested that unique regulatory idiotopes need not be postulated. 
We must note,  however, that  since only seven  MAb from that  immunization 
were studied, the result obtained can only be regarded as partial support for the 
regulatory idiotope concept. 
Finally, a second important type of support for the regulatory idiotope concept 
is our detection of one myeloma protein expressing the A48  Id in a  screen of 
198 non-BL-binding myelomas. This suggests that the A48 Id may be expressed 
relatively frequently. Again, we must add that no firm conclusion may be reached 
from only a  single positive monoclonal protein among a  small sample (198) of 
monoclonal proteins. 
The  finding  that  the  A48  Id  ÷  non-BL-binding  protein  is  specific  for  PC 
suggests that a  regulatory connection may exist between the antifructosan and 
anti-PC responses. This provides a valuable opportunity to examine consequences 
of immunization by one antigen on  an  idiotypically connected system. These 
studies are now in progress. 
Summary 
The ABPC-48 Id (A48 Id) is normally not expressed in detectable amounts in 
the serum of BALB/c mice that have been immunized with bacterial levan (BL). 
However, A48 Id-bearing anti-BL clones can be activated in BL-immunized mice 
by three distinct prior treatments: (a) administration of A48 Id-bearing mono- GOLDBERG, PAUL, AND BONA  527 
clonal proteins to newborn mice; (b) administration  of minute amounts of anti- 
Id antibodies to newborn mice; and (c) production of anti-(anti-A48 Id) antibodies 
(Abs),  in  adult  mice.  From  these  three  groups  of mice,  eighteen  monoclonal 
antibodies  (MAb)  expressing  A48  Id  were  obtained.  Regarding  the  binding 
specificity, these MAb can be divided into three groups: one that binds only BL, 
the second that  binds  BL and  displays low cross-reactivity for inulin,  and  the 
third  that lacks BL- and inulin-binding  activity. This latter group was obtained 
only from  adult  mice immunized  with  anti-A48  Id-KLH  conjugate.  Immuno- 
chemical analysis of these MAb has shown that the A48 Id is made up of several 
idiotopes, some of them associated with the combining site and others nonantigen 
inhibitable. 
Comparisons of the amino acid sequence of the UPC-10 and A48 VH regions, 
and  the  distribution  of the  A48  Id family on  A48,  UPC-10, and  three  MAb, 
suggested  that  A48  regulatory  idiotypes  can  be  located  on  the  framework 
segment of VH region.  Furthermore,  we screened  198  mouse and  80  human 
myeloma proteins for their ability to express A48 Id. Of these, only'MOPC-167, 
an IgAk phosphocholine (PC)-binding myeloma protein,  gave a significant inhi- 
bition of binding of labeled A48 to anti-A48 Id antibodies by radioimmunoassay 
and  enzyme-linked  immunosorbent  assay.  In  addition,  the  binding  of labeled 
MOPC-167 to anti-A48 Id antibodies was not inhibited by PC but was inhibited 
by A48  and  3-76-42  MAb bearing  A48,  UPC-10 non-antigen-inhibitable  idi- 
otopes. These results extend our prediction that the regulatory idiotopes can be 
expressed not only on antibodies specific for a family of antigens or members of 
the same network pathway, but also can be shared by antibodies with different 
antigenic specificity. 
Received for publication 14 March 1983 and in revised  form 21 April 1983. 
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